ResearcherUniversity of PisaNo recent work listed
Chiara Caparello
Matched on OpenAlex author ID A5086091185. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2016: 4 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper
Papers 6
- Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08297-z↗
- First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. First author DOI 10.1002/ijc.30125↗
- Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. Co-author DOI 10.1038/bjc.2016.69↗
- Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Co-author DOI 10.2217/fon.16.16↗
- FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Enrico Vasile · 6 shared papers, 2016–2020 · strength 0.43
- Paper Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenoca… DOI 10.1097/sla.0000000000003084↗
- Paper Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO… DOI 10.1038/bjc.2016.69↗
- Paper Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cance… DOI 10.1038/s41598-017-08297-z↗
- Caterina Vivaldi · 4 shared papers, 2016–2017 · strength 0.26
- Paper Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO… DOI 10.1038/bjc.2016.69↗
- Paper Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cance… DOI 10.1038/s41598-017-08297-z↗
- Paper First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis… DOI 10.1002/ijc.30125↗
- Lorenzo Fornaro · 4 shared papers, 2016–2017 · strength 0.26
- Paper Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO… DOI 10.1038/bjc.2016.69↗
- Paper Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cance… DOI 10.1038/s41598-017-08297-z↗
- Paper First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis… DOI 10.1002/ijc.30125↗
- Laura L. Meijer · 2 shared papers, 2016–2020 · strength 0.17
- Tessa Y. S. Le Large · 2 shared papers, 2016–2020 · strength 0.17
- Niccola Funel · 2 shared papers, 2016–2020 · strength 0.17
- Ingrid Garajová · 2 shared papers, 2016–2020 · strength 0.17
- Geert Kazemier M · 2 shared papers, 2016–2020 · strength 0.17
- Elisa Giovannetti · 2 shared papers, 2016–2020 · strength 0.17
- Silvia Catanese · 2 shared papers, 2016 · strength 0.12
- Adam Enver Frampton · 1 shared paper, 2020 · strength 0.11
- Eleonora Rofi · 1 shared paper, 2017 · strength 0.07
- Marzia Del Re · 1 shared paper, 2017 · strength 0.07
- Romano Danesi · 1 shared paper, 2017 · strength 0.07
- Godefridus J. Peters · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.